Jean-Marc Rolain

InstitutionAix Marseille Univ
AddressMarseille
France
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 20 Covid-19 publications, with a maximum of 7 publications in March 2020
    All Publications
    Bar chart showing 402 publications over 20 distinct years, with a maximum of 41 publications in 2016
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chamieh A, Zgheib R, El-Sawalhi S, Yammine L, El-Hajj G, Zmerli O, Afif C, Rolain JM, Azar E. Trends of Multidrug-Resistant Pathogens, Difficult to Treat Bloodstream Infections, and Antimicrobial Consumption at a Tertiary Care Center in Lebanon from 2015-2020: COVID-19 Aftermath. Antibiotics (Basel). 2021 Aug 21; 10(8). PMID: 34439065.
      Citations:    
    2. Kaba L, Giraud-Gatineau A, Jimeno MT, Rolain JM, Colson P, Raoult D, Chaudet H. Consequences of the COVID-19 Outbreak Lockdown on Non-Viral Infectious Agents as Reported by a Laboratory-Based Surveillance System at the IHU Méditerranée Infection, Marseille, France. J Clin Med. 2021 Jul 21; 10(15). PMID: 34361994.
      Citations:    
    3. Hache G, Rolain JM, Gautret P, Deharo JC, Brouqui P, Raoult D, Honoré S. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. Microb Drug Resist. 2021 Mar; 27(3):281-290. PMID: 33729874.
      Citations: 2     Fields:    Translation:Humans
    4. Dubourg G, Lagier JC, Brouqui P, Casalta JP, Jacomo V, La Scola B, Rolain JM, Raoult D. Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? J Microbiol Immunol Infect. 2021 Oct; 54(5):997-1000. PMID: 33632620.
      Citations: 1     Fields:    Translation:Humans
    5. Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, Leone M, La Scola B, Devaux C, Gaubert JY, Mege JL, Vitte J, Melenotte C, Rolain JM, Parola P, Lagier JC, Brouqui P, Raoult D. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020 12; 16(12):1159-1184. PMID: 33356661.
      Citations: 19     Fields:    Translation:Humans
    6. Lalaoui R, Bakour S, Raoult D, Verger P, Sokhna C, Devaux C, Pradines B, Rolain JM. What could explain the late emergence of COVID-19 in Africa? New Microbes New Infect. 2020 Nov; 38:100760. PMID: 32983542.
      Citations: 14     
    7. Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, Honoré S, Gaubert JY, Fournier PE, Tissot-Dupont H, Chabrière E, Stein A, Deharo JC, Fenollar F, Rolain JM, Obadia Y, Jacquier A, La Scola B, Brouqui P, Drancourt M, Parola P, Raoult D. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 Jul - Aug; 36:101791. PMID: 32593867.
      Citations: 103     Fields:    Translation:HumansCellsPHPublic Health
    8. Million M, Gautret P, Colson P, Roussel Y, Dubourg G, Chabriere E, Honore S, Rolain JM, Fenollar F, Fournier PE, Lagier JC, Parola P, Brouqui P, Raoult D. Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New Microbes New Infect. 2020 Nov; 38:100709. PMID: 33088574.
      Citations: 26     
    9. Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020 Jun; 53(3):425-435. PMID: 32414646.
      Citations: 151     Fields:    Translation:HumansCellsPHPublic Health
    10. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C, Eldin C, Tissot-Dupont H, Honoré S, Stein A, Jacquier A, Deharo JC, Chabrière E, Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, La Scola B, Parola P, Raoult D. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020 May - Jun; 35:101738. PMID: 32387409.
      Citations: 169     Fields:    Translation:HumansCellsPHPublic Health
    11. Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, Wurtz N, Rolain JM, Colson P, La Scola B, Raoult D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020 Aug; 145:104228. PMID: 32344177.
      Citations: 89     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    12. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Tissot-Dupont HT, Honoré S, Stein A, Million M, Colson P, La Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain JM, Brouqui P, Raoult D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar - Apr; 34:101663. PMID: 32289548.
      Citations: 282     Fields:    Translation:HumansCellsPHPublic Health
    13. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul; 56(1):105949. PMID: 32205204.
      Citations: 1940     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    14. Roussel Y, Giraud-Gatineau A, Jimeno MT, Rolain JM, Zandotti C, Colson P, Raoult D. SARS-CoV-2: fear versus data. Int J Antimicrob Agents. 2020 May; 55(5):105947. PMID: 32201354.
      Citations: 18     Fields:    Translation:HumansCellsPHPublic Health
    15. Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020 Apr; 55(4):105944. PMID: 32179150.
      Citations: 93     Fields:    Translation:HumansCellsPHPublic Health
    16. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May; 55(5):105938. PMID: 32171740.
      Citations: 379     Fields:    Translation:HumansCellsPHPublic Health
    17. Raoult D, Hsueh PR, Stefani S, Rolain JM. COVID-19 Therapeutic and Prevention. Int J Antimicrob Agents. 2020 04; 55(4):105937. PMID: 32151714.
      Citations: 9     Fields:    Translation:HumansCellsPHPublic Health
    18. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, Hsueh PR. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020 04; 55(4):105933. PMID: 32147516.
      Citations: 121     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    19. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 04; 55(4):105932. PMID: 32145363.
      Citations: 317     Fields:    Translation:CellsPHPublic Health
    20. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020 03; 55(3):105923. PMID: 32070753.
      Citations: 162     Fields:    Translation:AnimalsCellsPHPublic Health
    Rolain's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (320)
    Explore
    _
    Co-Authors (95)
    Explore
    _
    Similar People (60)
    Explore
    _